Breaking Down Establishment Labs Hldgs: 11 Analysts Share Their Views
Analysts' ratings for Establishment Labs Hldgs (NASDAQ:ESTA) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 2 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 1 | 0 | 0 |
Analysts have recently evaluated Establishment Labs Hldgs and provided 12-month price targets. The average target is $86.18, accompanied by a high estimate of $100.00 and a low estimate of $75.00. Marking an increase of 8.96%, the current average surpasses the previous average price target of $79.09.
Decoding Analyst Ratings: A Detailed Look
A clear picture of Establishment Labs Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| George Sellers | Stephens & Co. | Raises | Overweight | $90.00 | $85.00 |
| Anthony Petrone | Mizuho | Raises | Outperform | $100.00 | $90.00 |
| Sam Eiber | BTIG | Raises | Buy | $88.00 | $86.00 |
| Mike Matson | Needham | Raises | Buy | $86.00 | $84.00 |
| Mike Matson | Needham | Maintains | Buy | $84.00 | $84.00 |
| Sam Eiber | BTIG | Raises | Buy | $86.00 | $81.00 |
| Caitlin Cronin | Canaccord Genuity | Raises | Buy | $85.00 | $72.00 |
| Allen Gong | JP Morgan | Raises | Overweight | $80.00 | $71.00 |
| Anthony Petrone | Mizuho | Raises | Outperform | $90.00 | $85.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $75.00 | $62.00 |
| Mike Matson | Needham | Raises | Buy | $84.00 | $70.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Establishment Labs Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Establishment Labs Hldgs compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Establishment Labs Hldgs's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Establishment Labs Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Establishment Labs Hldgs analyst ratings.
About Establishment Labs Hldgs
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
A Deep Dive into Establishment Labs Hldgs's Financials
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Establishment Labs Hldgs's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 33.7%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -20.72%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -56.97%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.33%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Establishment Labs Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 15.96. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.